Fidson Healthcare Plc has reported a 49.47 per cent increase in pre-tax profit to N17.79 billion for the first nine months of 2026, as a sharp reduction in foreign exchange losses boosted its earnings.
The pharmaceutical company’s performance marks a significant improvement on the N11.90 billion pre-tax profit recorded in the corresponding period of 2025, with its latest earnings already surpassing the full-year figure for the previous year.
Brandspur Banking News Desk reports that Fidson’s unaudited financial statements, filed with the Nigerian Exchange Limited (NGX), show that the company’s pre-tax profit for the nine months ended September 30, 2026, exceeded the N14.96 billion recorded for the entire 2025 financial year.
The company’s profit after tax also climbed by 47.23 per cent to N11.74 billion, compared with N7.97 billion in the same period last year.
Revenue rose by 20.98 per cent to N112.61 billion, reflecting stronger sales during the reporting period.
The improvement in earnings comes as foreign exchange losses, which have weighed on the financial performance of several Nigerian businesses in recent years, declined sharply.
For pharmaceutical companies such as Fidson, exchange rate movements can significantly affect operating costs because imported medicines, raw materials and production inputs may require foreign currency.
See Also: Fidson Healthcare Selected To Manufacture Roche’s Flu Drug In 129 Countries
A reduction in foreign exchange losses can therefore provide relief to earnings, although the extent of the benefit depends on a company’s exposure to foreign currency transactions.
Fidson’s latest results indicate that the company is making progress in improving its profitability, with both revenue and after-tax earnings recording double-digit growth.
The performance also places the company ahead of its 2025 full-year pre-tax profit figure before the close of the 2026 financial year.
